(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 78.13% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Zymeworks's revenue in 2026 is $37,127,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $22,557,942,714, with the lowest ZYME revenue forecast at $18,894,317,101, and the highest ZYME revenue forecast at $29,210,371,558. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $19,123,515,450, with the lowest ZYME revenue forecast at $9,109,747,360, and the highest ZYME revenue forecast at $29,974,602,583.
In 2028, ZYME is forecast to generate $14,680,757,370 in revenue, with the lowest revenue forecast at $8,414,346,798 and the highest revenue forecast at $22,523,882,278.